Skip to content

Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor.

by on May 5, 2016

SourceClin Cancer Res. 2016 Mar 15.

Follow this link for abstract

Date of publication: March, 2016

Publication type: Research article

In a nutshell: New compounds may aid in development of targeted therapies for a rare paediatric cancer. Two recently discovered compounds have shown promise in pre-clinical studies for treating Ewing sarcoma, a rare cancer that predominantly affects children and adolescents. The goal of this study is to identify second-generation mithramycin analogs that better target the EWS-FLI1 transcription factor for Ewing sarcoma.

Some important notes: In case you experience difficulty obtaining this article,  please ask your local health librarian to locate this for you.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: